Alterity Therapeutics (ATHE)

Executive Summary

Alterity Therapeutics is a clinical-stage biotechnology company developing ATH434, an orally administered small molecule designed to inhibit the aggregation of pathological proteins such as alpha-synuclein and tau in neurodegenerative diseases. The company's lead program is focused on Parkinsonian conditions, including multiple system atrophy (MSA) and Parkinson's disease. ATH434 acts as a brain-penetrant metal protein attenuating compound, aiming to reduce toxic protein accumulation and slow disease progression. Currently, Alterity is conducting clinical trials evaluating ATH434's safety and tolerability in patients. The company is listed on the ASX under ticker ATHE and has a market capitalization of approximately $90 million. As a small-cap biotech, Alterity's near-term value is highly dependent on clinical data readouts and regulatory progress. The company's approach is unique in targeting metal-protein interactions, but the high risk of neurodegenerative disease trials and limited pipeline diversification contribute to significant execution risk.

Upcoming Catalysts (preview)

• Q2 2026Phase 2 data readout for ATH434 in MSA40% success
• Q4 2026FDA meeting or IND clearance for ATH434 in Parkinson's disease55% success
• TBDPotential partnership or licensing deal for ATH43430% success